The effects of dietary Yamabushitake mushroom (Hericium erinaceus) on lipid metabolism were examined. C57BL/6J mice were fed a high-fat diet containing hot-water extract (HW-E) and an ethanol extract (EtOH-E) of Yamabushitake mushroom. Administration of HW-E or EtOH-E with a high-fat diet for 28 d resulted in a significant decrease in body weight gain, fat weight, and serum and hepatic triacylglycerol levels. Our in vitro experiments indicated that EtOH-E acts as an agonist of peroxisome proliferator-activated receptor (PPAR). Quantitative analyses of hepatic mRNA levels revealed that EtOH-E administration resulted in up-regulation of mRNA for a number of PPARregulating genes in spite of the fact that the gene expression of PPAR did not change. These results suggest that EtOH-E improves lipid metabolism in mice fed a high-fat diet, and that these effects were mediated by modulation of lipid metabolic gene expression, at least in part via activation of PPAR.
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Key words: Yamabushitake mushroom; Hericium erinaceus; lipid metabolism; peroxisome proliferator-activated receptor (PPAR) In developed countries, obesity is an important health problem. Half or more of the adult population is now identified as overweight (body mass index or BMI > 25 kg/m 2 -30 kg/m 2 ) or obese (BMI ! 30 kg/m 2 ) in no less than 11 member countries of the Organization for Economic Cooperation and Development (OECD). 1) Obesity is one of the significant risk factors for metabolic syndrome, which include hypertension and hyperlipidemia, potentially leading to type-2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease. 2, 3) Recently, it was reported that several food components have an anti-hyperlipidemia effect in vivo. For example, isohumulones, 4) bitter acids derived from hops, and sesamin, a sesame lignan, 5) improve lipid metabolism in rodents. We have screened the anti-obesitic activities of wild plants and mushrooms, and isolated lupeol, 6) a lupane-type triterpene from Chinese dandelion root, and ethanol extract from edible shoots of giant butterbur (Petasites japonicus) 7) as active compounds. Yamabushitake mushroom (Hericium erinaceus) is a popular edible mushroom in east Asia. It is utilized as a traditional Chinese medicinal mushroom. Kawagishi et al. reported that hericenones 8) and erinacines, 9) components of the fruiting body of Yamabushitake mushroom, can promote nerve growth factor synthesis in cultured astrocytes. Oral administration of dried Yamabushitake mushroom powder is effective in improving mild cognitive impairment in humans, 10) but little is known about the anti-obesity efficacy of Yamabushitake mushroom.
Here we investigated the lipid metabolism-improving effects of dietary-administered extracts of Yamabushitake mushroom in mice fed a high-fat diet, examined the extracts for the ligand activity of the nuclear receptor, and analyzed the expression levels of the genes involved in lipid metabolism in the mice to elucidate the detailed mechanism.
Materials and Methods
Preparation of Yamabushitake mushroom extract. We used two types of Yamabushitake mushroom extract as test substances, a hotwater extract (HW-E) and an ethanol extract (EtOH-E). Fruiting bodies of Yamabushitake, cultured by us, were oven-dried and ground in a jet mill. First, 200 g of dry powder of Yamabushitake (moisture 9.5%, protein 9.6%, lipid 2.6%, ash 5.1%, carbohydrate 25.7%, dietary fiber 47.5%) was suspended in hot water (2.0 liters). After 2 h, treatment at 85 C, the suspension was filtered and then lyophilized; the final product (48 g) was the HW-E. Secondly, 400 g of dry powder of Yamabushitake was agitated in 8.0 liters of ethanol for 16 h at room temperature and then filtered. The filtrate was evaporated. The final product (60 g) was the EtOH-E.
Animal experiment. C57BL/6JJcl mice (6 weeks old, male) were purchased from CLEA Japan (Tokyo). They were housed in polycarbonate cages in a room maintained at 23 AE 2 C under a 12-h lightdark cycle (8:00-20:00). They had free access to fresh diet and drinking water during the experimental period. They were fed High Fat Diet 32 (HFD, CLEA Japan) for 7 d, and were divided into three y To whom correspondence should be addressed. Tel: +81-22-717-8812; Fax: +81-22-717-8813; E-mail: shirakah@biochem.tohoku.ac.jp Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; C, control diet; EtOH, ethanol extract diet; EtOH-E, ethanol extract; HDL-C, high-density lipoprotein cholesterol; HFD, High-Fat Diet 32; HW, hot-water extract diet; HW-E, hot-water extract; LDL-C, low-density lipoprotein cholesterol; NEFA, nonesterified fatty acid; OECD, Organization for Economic Cooperation and Development; PCR, polymerase chain reaction; PL, phospholipids; PPAR, peroxisome proliferator-activated receptor ; RCAS, Receptor Coactivator Ligand Assay System; SEM, standard error of the mean; TC, total cholesterol; TG, triacylglycerol groups of six mice each: control diet (C), hot-water extract diet (HW), and ethanol extract diet (EtOH), and the six mice in a given group were housed in identical polycarbonate cages. The composition of the HFDbased experimental diets is shown in Table 1 . HW and EtOH were supplemented with 2% of HW-E and EtOH-E as the test substances. Determinations of the actual diet composition were performed by the Akita Foundation For Health Care (Akita, Japan). All test diets were administered for 28 consecutive d. Food intake was recorded every day, and body weight was measured once every 2 or 3 d. At the end of the experimental period, the mice were sacrificed under light diethyl ether anesthesia after 16 h of fasting. Blood was collected from the abdominal aorta, and the serum obtained was stored at À20 C until analysis. Livers, mesenteric and epididymal adipose tissues were excised, weighed, and frozen at À80 C until analysis. The experimental plan of the study was approved by the Ethics Committee for Animal Experimentation of the Akita Research Institute for Food and Brewing. The entire experiment closely followed the guidelines issued by the Committee, which strictly follows government legislation in Japan.
Serum and liver parameters. Serum levels of glucose, total cholesterol (TC), triacylglycerol (TG), high-density lipoprotein cholesterol (HDL-C), aspartate transaminase (AST), and alanine transaminase (ALT) were measured with an automatic analyzer (Fuji DRI-CHEM 3500V; Fujifilm, Tokyo). The concentration of low-density lipoprotein cholesterol (LDL-C) was calculated by Friedewald's formula.
11) The serum nonesterified fatty acid (NEFA) level was determined by enzymatic colorimetric methods (Wako Pure Chemical Industries, Osaka, Japan). Levels of serum leptin and adiponectin were determined by sandwich enzyme-linked immunoassay (Morinaga Institute of Biological Science, Kanagawa, Japan, and Otsuka Pharmaceutical, Tokyo, respectively). The procedure for sample pretreatment and measurement was carried out according to the instruction manuals. Liver lipids were determined following Folch et al. 12) Liver TC, TG, and phospholipid (PL) concentrations were determined using enzymatic colorimetric kits (Sekisui Chemical, Tokyo), following extraction of liver samples with chloroformmethanol (2:1, v/v).
Peroxisome proliferator-activated receptor (PPAR) agonist assay. PPAR competitive binding assays were performed by EnBioTec Laboratories (Tokyo) using a PPAR/Receptor Coactivator Ligand Assay System (RCAS) following the protocol. RCAS can detect agonistic activity without antagonistic activity. In brief, a mixture of recombinant human PPAR and samples was added to the wells of a plate coated with biotinylated coactivator peptide, and this was allowed to react at room temperature for 1 h. After washing of the wells with wash solution, anti-PPAR-horseradish peroxidase solution was added to each well. The absorbance at 450 nm was measured with a microplate reader after incubation with the chromogen. Wy14643 (Cayman Chemical, Ann Arbor, MI), a selective PPAR agonist, was used as positive control.
RNA preparation and quantitative real-time polymerase chain reaction (PCR). Total RNA was isolated from the liver with a silicamembrane spin column kit, an RNeasy Maxi Kit (Qiagen, Hilden, Germany) following the instruction manual. The wavelength ratios at 260 and 280 nm and capillary electrophoresis using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) were measured to facilitate quantitative and qualitative analysis of isolated RNA. Template cDNA synthesis was performed with 5 mg of total RNA using a PrimeScript RT reagent Kit (Takara Bio, Shiga, Japan) following the manufacturer's instructions. Aliquots of cDNA were used as a template for subsequent quantitative real-time-PCR using Chromo4 (Bio-Rad Laboratories, Hercules, CA). cDNA samples in 25 ml of 1Â SYBR Premix Ex Taq (Takara Bio) containing 0.2 mM of each primer were incubated in the thermal cycler for initial denaturation at 95 C for 10 s, followed by 40 PCR cycles. Each cycle consisted of 95 C for 5 s and 60 C for 30 s. The oligonucleotide primers used in the experiment are indicated in Table 2 . To confirm amplification of specific transcripts, melting curve profiles (cooling the sample to 60 C and to 95 C with continuous measurement of fluorescence) were produced at the end of each PCR. The relative expression levels of gene expression were normalized by the amount of -actin (Actb) mRNA.
Statistical analysis.
Values are presented as means and standard errors (SEM). To evaluate differences among the groups studied, oneway ANOVA was followed by Dunnett's post hoc test ( Fig. 1 and Table 3 ) and Student's t-test (Fig. 3) . GraphPad Prism 5.0-J (MDF, Tokyo) was used to analyze all data. Probability values of p < 0:05 were considered significant.
Results
Food intake, body weight, and body fat Daily food intake per cage did not differ among the groups in this experiment ( Table 1 ). The EtOH mice were significantly lighter than the C mice by day 24 of treatment. These trends continued throughout the treatment period (Fig. 1) . By the end of the 28-d treatment period, the body weights of the HW and EtOH groups were significantly lower than the C group. On average, BW gain was 30.0% lower in the HW mice and 42.4% lower in the EtOH mice than in the C mice. The results of tissue harvesting indicated that mesenteric adipose tissue in the HW and EtOH groups was significantly smaller than in the C group (32.4% and 38.5% decreases, respectively). In contrast, the weights of epididymal adipose tissue did not change among the groups. Table 3 shows the serum parameters recorded in the present experiment. The HW and EtOH groups showed significantly lower serum TG levels than the C group (8.0% and 27.1% decreases, respectively). HW and EtOH did not influence TC, HDL-C, or NEFA, but the average LDL-Cs in the HW and EtOH groups were lower than in the C group, although the differences were not significant. At the end of the experiment, the serum glucose level in the HW group was significantly lower than in the C group, but there was no significant difference between the EtOH and the C group. AST, ALT, adiponectin, and leptin did not change significantly, but in the HW and EtOH groups, serum adiponectin levels were higher and leptin levels were lower than in the C group.
Serum parameters

Hepatic lipid profile
The hepatic TG levels in HW and EtOH groups were significantly lower than in the C group (29.8% and 38.8% decreases, respectively). The EtOH mice had significantly higher liver PL. The Yamabushitake extracts did not influence liver TC.
PPAR ligand assay
The PPAR agonist activities of HW-E and EtOH-E were determined in RCAS. Figure 2 shows a summary of the results obtained in the two assays. The dose response of EtOH-E was fitted to a sigmoid model like the dose response of Wy14643 as a positive control. EtOH-E acted as an agonist of PPAR at EC 50 ¼ 40:0 mg/ml. In contrast, HW-E did not show agonistic activity toward the same receptor.
Hepatic mRNA expression levels
The mRNA expression levels of lipid metabolic genes in the liver are shown in Fig. 3 . We found no change in the expression of PPAR (ppara) between the C and the EtOH group (Fig. 3A) , but the EtOH group had significantly increased mRNA levels of PPARregulating genes, viz., fatty acid transport protein 1 (Slc27a1), fatty acid transport protein 4 (Slc27a4), acylCoA dehydrogenase, medium chain (Acadm), and acylCoA dehydrogenase, long-chain (Acadl), and tended to have a higher level of apo A-I (Apoa1) and lipoprotein lipase (Lpl). There was no change in the expression of acyl-CoA synthetase long-chain family member 1 (Acsl1), and the EtOH group showed significant downregulation in mRNA levels of palmitoyl acyl-CoA oxidase 1 (Acox1) (Fig. 3B) . Other lipid metabolic genes, sterol regulatory element binding factor 1 (Srebf1) and acetyl-CoA carboxylase (Acaca), were significantly upregulated, and the fatty acid synthase (Fasn) gene tended to be upregulated in the EtOH group.
Discussion
Hyperlipidemia is a significant risk factor for the development of atherosclerosis, cardiovascular disease, and nonalcoholic fatty liver disease.
3) In this study, we used mice fed a high-fat diet as an animal model of obesity and hyperlipidemia, 13) and evaluated the antiobesitic effects of two Yamabushitake mushroom extracts, HW-E and EtOH-E, on the lipid metabolism of the mice. As for the results, HW-E and EtOH-E decreased body weight gain, mesenteric adipose tissue weight, and serum and hepatic TG levels in the mice as compared to C. No meaningful differences in the food intakes of the three groups were detected. These results suggest that the two extracts from Yamabushitake mushroom selectively reduced body weight gain and mesenteric adipose tissue weights without affecting food intake.
PPAR, a nuclear receptor-type transcriptional factor, is widely expressed in the liver, muscle, kidney, and intestine, and regulates expression of the genes involved in lipid metabolism. Activators of PPAR, such as fibrates and isohumulones, lower body weight gain, retroperitoneal adipose tissue weight, plasma TG level, and hepatic TG content. 4, [14] [15] [16] We investigated to determine whether activation of PPAR is involved in the anti-obesity effects of Yamabushitake mushroom Ã p < 0:05; ÃÃ p < 0:01. Ppara, peroxisome proliferator-activated receptor (PPAR); Apoa1, apo A-I; Lpl, lipoprotein lipase; Slc27a1, fatty acid transport protein 1; Slc27a4, fatty acid transport protein 4; Acsl1, acyl-CoA synthetase long-chain family member 1; Acox1, palmitoyl acyl-CoA oxidase 1; Acadm, acyl-CoA dehydrogenase, medium chain; Acadl, acyl-CoA dehydrogenase, long-chain; Srebf1, sterol regulatory element binding factor 1; Fasn, fatty acid synthase; Acaca, acetyl-CoA carboxylase extracts in mice fed a high-fat diet. An in vitro RCAS assay demonstrated that EtOH-E contains PPAR ligand. Quantitative real-time PCR analysis indicated that EtOH-E supplementation did not change the hepatic gene expression of PPAR and upregulated the gene expression of Slc27a1, Slc27a4, Acadm, and Acadl regulated by PPAR. 17, 18) The proteins encoded by Lpl, Slc27a, and Acad mRNA are involved in hydrolysis of the TG moiety of chylomicron and VLDL particles, translocation of fatty acids across the plasma membrane, and the initial step of mitochondrial -oxidation of straight-chain fatty acids, respectively. 19) Therefore, upregulation of these genes by EtOH might result in normalizing serum and hepatic TG levels by stimulation of -oxidation potentials in the liver. Some studies have indicated that the Acsl1 and Acox1 genes are also regulated by PPAR. In the present study, EtOH-E did not markedly affect the expression of these genes. The reason remains unclear, but not only PPAR but also other regulators might play important roles in gene expression. Moreover, quantitative RT-PCR analysis of mRNA from the liver indicated that the expression of Srebf1, Fasn, and Acaca, which is involved in the transcription of the adipogenetic gene, the synthesis of saturated fatty acids, and the carboxylation of acetylCoA respectively, 19, 20) were significantly increased, or tended to increase. These data suggest that alternative components of EtOH-E, other than the PPAR agonist, also modulate lipid metabolism in mice fed a high-fat diet.
HW-E also reduced serum TG levels in the mice, but the extracts did not exhibit PPAR agonist activities in vitro. Furthermore, HW supplementation significantly downregulated hepatic gene expression of PPAR, Slc27a4, and Acadm on quantitative real-time PCR analysis (data not shown). This data suggests that the mechanism of the improvement of lipid metabolism in the HW-fed mice differed from that in the EtOH-fed mice. Water-soluble dietary fiber in HW-E might have been involved in the inhibitory effects on serum TG levels.
In conclusion, we found that EtOH-E prevented dietinduced obesity and hyperlipidemia, and that these effects might be mediated by the modulation of lipid metabolic gene expression, at least in part, via activation of PPAR.
